| Objective: To investigate the expression of leukemia stem cell-associated antigen in acute myeloid leukemia and its relationship with clinical efficacy,and to monitor the significance of micro-residues.Methods:A total of 160 newly diagnosed patients with acute myeloid leukemia who were hospitalized in the Department of Hematology of our hospital from January 2013 to May 2016 were selected for the study.Flow cytometry was used to detect the expression of CD34,CD123,CD117 and HLA-DR.Results: 1.The order of expression was CD123(78.8%),CD117(76.3%),HLA-DR(51.9%),and CD34(41.9%).CD117 and CD123 were expressed in each AML subtype.The expression of CD34 and HLA-DR antigens was mostly found in M1,M2,and M4,and was extremely low in M3.2.In this group of data,160 cases of AML patients received induction remission therapy,CR112 cases,CR rate of 70%.The CR rate of the CD34 and CD123 positive groups was lower than that of the negative group.There was a statistically significant difference between the two groups(P values were 0.000,0.046,respectively).The CR rate of the CD34 and CD117,CD123,HLA-DR co-expression group was lower than the non-co-expression group CR rate,and the difference was statistically significant(P<0.001).3.In the minimal residue test,the recurrence rates of CD34,CD117,CD123,and HLA-DR antigens in groups above 1% were 32.3%,11.4%,19.2%,and 11.2%,respectively.(P values are < 0.001)can be used as indicators of monitoring of small residuals in patients with AML.Conclusions:1.To clarify the expression of leukemia stem cell-associated antigen in AML patients.2.The expression of CD34,CD123 antigen and the co-expression of CD34 and CD117,CD123,HLA-DR were negatively correlated with the clinical efficacy of AML patients.3.CD34,CD123 and CD117,CD123,HLA-DR antigens can be used as indicators for the detection of MRD in patients with AML,and have important significance for the detection of minimal residual disease in AML. |
PDF Full Text Request